# $nktr

Nektar Therapeutics faces ongoing legal battles with Eli Lilly, with a jury trial set for September 8, 2026, creating significant uncertainty. Meanwhile, positive sentiment surrounds its clinical data and pipeline potential, particularly in dermatology.

### About $nktr
Nektar Therapeutics is a biotechnology company focused on developing innovative therapies.  

### Insights
- $nktr mentions hit [---] which is 167% higher than it's daily average.

### Engagements: [-------] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$nktr/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$nktr/time-series/interactions.tsv)  
Current Value: [-------]  
Daily Average: [------]  
[--] Week: [------] -31%  
[--] Month: [---------] -10%  
[--] Months: [----------] +49%  
[--] Year: [----------] +1,893%  
1-Year High: [---------] on 2025-06-24  
1-Year Low: [---] on 2025-04-08  

Engagements by network (24h):
Reddit: [--]
YouTube: [--]
X: [-------]

  
  
### Mentions: [---] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$nktr/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$nktr/time-series/posts_active.tsv)  
Current Value: [---]  
Daily Average: [---]  
[--] Month: [---] +100%  
1-Year High: [-----] on 2025-06-25  
1-Year Low: [--] on 2025-05-27  

Mentions by network (24h):
Reddit: [--]
YouTube: [--]
X: [---]

  
  
### Creators: [---] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$nktr/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$nktr/time-series/contributors_active.tsv)  
[---] unique social accounts have posts mentioning $nktr in the last [--] hours which is down 2.30% from [---] in the previous [--] hours
Daily Average: [---]  
[--] Month: [--] +56%  
1-Year High: [-----] on 2025-06-25  
1-Year Low: [--] on 2025-05-24  

The most influential creators that mention $nktr in the last [--] hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@A_May_MD](/creator/twitter/A_May_MD)               | [--]    | [------]    | [--]    | [------]      |
| [@financebully](/creator/twitter/financebully)       | [--]    | [-----]     | [--]     | [------]      |
| [@BiopharmIQ](/creator/twitter/BiopharmIQ)           | [--]    | [------]    | [--]    | [------]      |
| [@HOThomasWPhelps](/creator/twitter/HOThomasWPhelps) | [--]    | [-----]     | [--]    | [-----]       |
| [@semodough](/creator/twitter/semodough)             | [--]    | [------]    | [--]    | [-----]       |
| [@zohmbastic](/creator/twitter/zohmbastic)           | [--]    | [------]    | [--]     | [-----]       |
| [@RNAiAnalyst](/creator/twitter/RNAiAnalyst)         | [--]    | [------]    | [--]     | [-----]       |
| [@PersimmonTI](/creator/twitter/PersimmonTI)         | [--]    | [------]    | [--]     | [-----]       |
| [@seedy19tron](/creator/twitter/seedy19tron)         | [--]    | [------]    | [--]    | [-----]       |
| [@tradingsssss](/creator/twitter/tradingsssss)       | [--]   | [-----]     | [--]     | [-----]       |

[View More](/list/creators/$nktr/100)
  
  
### Sentiment: 73%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$nktr/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$nktr/time-series/sentiment.tsv)  
Current Value: 73%  
Daily Average: 81%  
[--] Week: 89% -11%  
[--] Month: 72% +14%  
[--] Months: 72% -14%  
[--] Year: 72% -28%  
1-Year High: 100% on 2025-02-16  
1-Year Low: 33% on 2025-03-31  

Most Supportive Themes:
- Positive Stock Performance and Analyst Confidence: (40%) Multiple posts highlight Nektar's (NKTR) recent stock performance, with some noting significant gains since previous pitches. Analysts express confidence in the company's valuation and future potential, even comparing it favorably to competitors.
- Clinical Data and Pipeline Potential: (30%) Discussions revolve around Nektar's clinical data, particularly in dermatology, with comparisons to competitor drugs like Dupixent. The potential for dual indications and efficient P3 studies is seen as a significant tailwind.
- Strategic Moves and Executive Changes: (20%) Posts mention Nektar's ongoing legal situations and recent executive changes, such as the Chief Legal Officer's departure and subsequent move to Septerna. These events are noted in the context of the company's broader strategic landscape.
  
Most Critical Themes:
- Legal Battles and Uncertainty: (70%) Nektar's legal proceedings, particularly with Eli Lilly (LLY), are a recurring theme, creating an undercurrent of uncertainty. The resolution of these cases is seen as a key factor influencing the stock's trajectory.
- Competitive Landscape and Alternative Investments: (30%) Some posts suggest alternative investment opportunities or compare Nektar unfavorably to competitors, indicating that the market may be overlooking other promising biotech plays. This highlights the competitive nature of the sector.
  

### Top $nktr Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"Now finally people are waking up to my thesis on $NKTR last [--] years the brokers are under valuing it on targets. Smarties know its going to be a blockbuster high odds will replace Dupixent. Remember at $36 I said todays price will be tomorrow EPS. Where were you at $7 🫠"  
[X Link](https://x.com/InfoBreakout/status/2022863494270361606) [@InfoBreakout](/creator/x/InfoBreakout) 2026-02-15T02:40Z [---] followers, [---] engagements


"$NKTR $CRVS $NKTR $CRVS don't understand the animosity between the two names both work on tregs and $NKTR's data provides a nice read through to $CRVS drug and vice versa most BPs talk about this and this is being talked about the same way with $ABVX and obefazimod in IBD but a safe $NKTR $CRVS don't understand the animosity between the two names both work on tregs and $NKTR's data provides a nice read through to $CRVS drug and vice versa most BPs talk about this and this is being talked about the same way with $ABVX and obefazimod in IBD but a safe"  
[X Link](https://x.com/tradingsssss/status/2022831506956198307) [@tradingsssss](/creator/x/tradingsssss) 2026-02-15T00:33Z [----] followers, [----] engagements


"$NKTR $LLY $NKTR Here's a nugget from a friend. Two Seas Capital just bought a chunk of NKTR. Two Seas is a litigation-specialist investor (not a biotech investor). The fund's PM is an attorney. The $LLY trial starts in September and Two Seas sure seems to think that $NKTR is going to get https://t.co/PSuWbn3g2B $NKTR Here's a nugget from a friend. Two Seas Capital just bought a chunk of NKTR. Two Seas is a litigation-specialist investor (not a biotech investor). The fund's PM is an attorney. The $LLY trial starts in September and Two Seas sure seems to think that $NKTR is going to get"  
[X Link](https://x.com/AponiaAnalytics/status/2022816196429557994) [@AponiaAnalytics](/creator/x/AponiaAnalytics) 2026-02-14T23:32Z [----] followers, [---] engagements


"@semodough 100%. $nktr $crvs will be the leaders in AtD"  
[X Link](https://x.com/wz2013/status/2022801533751197771) [@wz2013](/creator/x/wz2013) 2026-02-14T22:34Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing